XORTX Therapeutics Inc.
XRTXHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, XORTX Therapeutics Inc. focuses on Biotechnology services and products. XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat hyperuricemia related diseases in Canada. Valued at $3.5M, XRTX is a micro-cap name in its sector. It develops XRx-026, which is in Phase III for the treatment of gout; XRx-008, which is in Phase II for the treatment of autosomal dominant polycystic kidney disease; XRx-101, which is in Phase II for the treatment of acute kidney injury associated with respiratory virus infection, including sepsis and coronavirus; and XRX-225, which is in preclinical stage for the treatment of type 2 diabetic nephropathy, as well as VB4-P5, a program for the treatment and prevention of fibrosis in the kidney.
Market Cap
$3.5M
Beta
0.17
P/E (TTM)
—
P/E (Fwd)
2.54
EPS (TTM)
$-2.49
EPS (Fwd)
$0.80
ROE
-137.4%
ROA
-53.8%
Cash
$250,275
Total Debt
$15,056
Free CF
-$1.6M
52W Change
-57.0%
Annual Financials
Cash vs Debt
Where XRTX stands vs its 150-day and 200-day moving averages
As of the July 14, 2026 close, XRTX finished 16.12% below its 150-day moving average ($2.42) and 24.81% below its 200-day moving average ($2.70). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is XRTX overbought or oversold?
At the July 14, 2026 close, XRTX's RSI(14) was 47.4, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $250K in cash and $15K in debt, XRTX maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$1.6M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -137.4% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
The relatively low beta of 0.17 suggests XRTX is a less volatile holding compared to the broader index. With cash comfortably exceeding debt, XRTX has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for XORTX Therapeutics Inc. and its sector.